Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma Clinical Trial

Official title:

Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) With Pembrolizumab, in Subjects Who Have Failed Cisplatin-Based Chemotherapy With Locally Advanced (Unresectable) or Metastatic Transitional Cell Cancer (TCC) of the Urothelium

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03935347
• Other study ID #: I 77218
• Secondary ID: P30CA16056OD
• Status: Withdrawn
• Phase: Phase 2
• Start date: June 20, 2019
• Est. completion date: May 1, 2023

Study information

• Verified date: December 2019
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well autologous tumor infiltrating lymphocytes (LN-145) and pembrolizumab work in treating patients with transitional cell cancer that cannot be removed by surgery or has spread to other places in the body and have failed cisplatin-based chemotherapy. LN-145 is made up of specialized immune cells called lymphocytes or T cells that are taken from a patient's tumor, grown in a manufacturing facility and infused back into the preconditioned patient to attack the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving LN-145 may help control transitional cell bladder cancer when given together with pembrolizumab

Description:

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of autologous tumor infiltrating lymphocytes LN-145 (LN-145) in combination with pembrolizumab in subjects with advanced transitional cell bladder cancer (TCC) using the objective response rate (ORR) and the duration of response (DoR), using the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST version [v] 1.1).

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of LN-145 in combination with pembrolizumab in subjects with TCC based on the progression-free survival (PFS) and overall survival (OS).

II. To evaluate the safety of LN-145 in combination with pembrolizumab in subjects with TCC based on the adverse event (AE) profile per Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 1, 2023
• Est. primary completion date: May 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The subject must understand the requirements of the study and voluntarily sign the informed consent form (ICF)

• All subjects must have a histologically confirmed unresectable TCC (including renal pelvis, ureters, urinary bladder, and urethra)

• Failed one and only one line of cisplatin-based chemotherapy per FDA guidelines.

• Subjects must have an area of tumor amenable to excisional biopsy for the generation of TIL separate from, and in addition to , a target lesion to be used for response assessment.Have at least one resectable lesion to generate TILs

• At least one measurable target lesion as defined by RECIST version 1.1

• An Eastern Cooperative Oncology Group (ECOG) performance status of =< 1

• Estimated life expectancy of >= 6 months

• Adequate bone marrow function

• Adequate organ function

• Subjects must be seronegative for the human immunodeficiency virus (HIV)

• Recovered from all prior anticancer therapy-related AEs to grade 1 or less

• Negative serum pregnancy test (female subjects of childbearing potential)

• Subjects of childbearing potential must be willing to practice an approved method of birth control starting at the time of informed consent and for 12 months after the completion of the study treatment regimen

• Must be able and willing to comply with the study visit schedule and protocol requirements including long-term follow-up

Exclusion Criteria:

• Have had another primary malignancy within the previous 3 years (with the exception of carcinoma in situ of the breast, cervix, or localized prostate cancer and non-melanoma skin cancer that has been adequately treated)

• Have received prior cell transfer therapy that included a nonmyeloablative or myeloablative chemotherapy regimen

• Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or pathway-targeting agents

• Chemotherapy or radiotherapy with projected completion within 4 weeks of initiating study treatment

• Bisphosphonate therapy for symptomatic hypercalcemia

• Have had treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks before initiation of study treatment

• Active or prior documented autoimmune or inflammatory disorders

• Subjects who have any form of human immondeficiency virus (HIV)infection

• Have severe infections within 4 weeks before initiation of study treatment

• Have received a live or attenuated vaccine within 28 days of the non-myeloablative lymphodepletion (NMA-LD regimen)

• Subjects with a history of hypersensitivity reaction(s) to any component of the LN-145 therapy and/or the other study drugs

• Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) >= 450 msec for males (and >= 470 msec for females) calculated from 3 electrocardiograms (ECGs) (within a 30-minute timeframe) or history of familiar long-QT syndrome

• Subjects who have a left ventricular ejection fraction (LVEF) < 45% or who are New York Heart Association functional classification class II or higher

• Serious illnesses or medical conditions, which would pose increased risk for study participation and/or compliance with the protocol

• Known clinically significant liver disease

• Have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of =< 60%

• Subjects with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases

• Subjects who are pregnant or breastfeeding

• Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or human immunodeficiency virus

• Treatment with any other investigational agent within 4 weeks before initiation of study treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Metastatic Bladder Urothelial Carcinoma
• Metastatic Renal Pelvis Urothelial Carcinoma
• Metastatic Ureter Urothelial Carcinoma
• Metastatic Urethral Urothelial Carcinoma
• Unresectable Renal Pelvis Urothelial Carcinoma
• Unresectable Ureter Urothelial Carcinoma

Intervention

Drug:
• Cyclophosphamide
Given IV
• Fludarabine
Given IV
• Fludarabine Phosphate
Given IV

Biological:
• Pembrolizumab
Given IV
• Autologous Tumor Infiltrating Lymphocytes LN-145
Given IV
• Aldesleukin
Given IV

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (2)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute	Iovance Biotherapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate	The proportion of subjects who achieve either a confirmed partial response (PR) or complete response (CR) as best response as assessed per Response Evaluation Criteria in Solid Tumors 1.1. Will be evaluated per each disease assessment and calculated with the corresponding 95% two-sided confidence interval	Up to 3 years
Secondary	Incidence of adverse events (AEs)	Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5 by grade of severity and relationship to the study treatment.	From the first dose of cyclophosphamide up to 30 days from the last dose of IL-
Secondary	Duration of response	Will be assessed by Kaplan-Meier methods	Up to 3 years
Secondary	Disease Control Rate	Derived as the sum of the number of subjects who achieved confirmed PR/CR or sustained stable disease (at least 6 weeks) divided by the number of subjects in the all-treated population x 100%. Will be assessed by Kaplan-Meier methods	Up to 3 years
Secondary	Progression-free survival	Will be assessed by Kaplan-Meier methods	Up to 3 years
Secondary	Overall Survival	From time of lymphodepletion to death due to any cause	Up to 3 years